medigraphic.com
Instituto Nacional de Salud Pública

2012, Number 6

<< Back Next >>

salud publica mex 2012; 54 (6)

Malformaciones congénitas en hijos de madres epilépticas con y sin tratamiento con anticonvulsivantes

Arteaga-Vázquez J, Luna-Muñoz L, Mutchinick OM

Language: Spanish
References: 30
Page: 579-586
PDF size: 104.57 Kb.


ABSTRACT

Objective. To determine the prevalence at birth and type of congenital malformations (CM) in newborns of epileptic mothers (NEM) treated and not treated with anticonvulsants, the correlation anticonvulsant/CM and other developmental disorders. Materials and methods. Multicenter casecontrol study, in 166 live births NEM diagnosed in 21 501 newborns with CM and respective controls from the Registro y Vigilancia Epidemiológica de Malformaciones Congénitas (RYVEMCE). Results. The frequency of CM in NEM treated with anticonvulsants was higher (48.3%) than in NEM of untreated mothers (28.3%), (OR= 2.37 IC95% 1.08-5.40), p=0.03. CMs most frequently found were: spina bifida, limb reduction defects, cleft lip palate, microcephaly, anotia/microtia, hypospadias, polydactyly, cleft palate, anophthalmia/ microphthalmia and omphalocele. No differences among monotherapy and polytherapy were observed. Diphenylhydantoin, carbamazepine and valproic acid were the most frequently anticonvulsants used. Conclusions. Our results show the teratogenicity of epilepsy by itself, the synergistic effect of some anticonvulsants, and the need of an appropriate periconceptional control of the disease and treatment.


REFERENCES

  1. Organización Mundial de la Salud. Epilepsia, nota descriptiva No. 999 [monografía en internet]. Estados Unidos de América: Oficina Regional de la OMS para las Américas (AMRO), 2012 [Consultado 2012 enero 14]. Disponible en: http://www.who.int/mediacentre/factsheets/fs999/es/ index.html

  2. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc 1996;71:576-586.

  3. Kalter H. Teratology in the 20th century: environmental causes of congenital malformations in humans and how they were established. Neurotoxicol Teratol 2003;25:131-282.

  4. Quet F, Preux PM, Huerta M, Ramirez R, Abad T, Fragoso G, et al. Determining the burden of neurological disorders in populations living in tropical areas: who would be questioned? Lessons from a Mexican rural community. Neuroepidemiology 2011;36:194-203.

  5. Hiilesmaa VK, Teram K, Bardy AH. Social class, complications, and perinatal deaths in pregnancies of epileptic women: preliminary results of the prospective Helsinki study. En: Janz D et al, eds. Epilepsy, Pregnancy and the child. New York: Raven Press, 1982;3-14.

  6. Yerby MS, Kaplan P, Tran T. Risks and management of pregnancy in women with epilepsy. Cleve Clin J Med 2004; 71 suppl 2:S25-S37.

  7. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-198.

  8. Jentink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010;362:2185-2193.

  9. Bodendorfer TW. Fetal effects of anticonvulsant drugs and seizure disorders. Drug Intell Clin Pharm 1978;12:1421.

  10. Janz D, Fuchs U. Are anti-epileptic drugs harmful during pregnancy? Dtsch Med Wochenschr 1964;89:241-248.

  11. Meadow SR. Congenital abnormalities and anticonvulsant drugs. Proc R Soc Med 1970;63:48-49.

  12. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324:674-677.

  13. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Seizure 2008;17:166-171.

  14. Swartjes JM, van Geijn HP. Pregnancy and epilepsy. Eur J Obstet Gynecol Reprod Biol 1998;79:3-11.

  15. Artama M, Ritvanen A, Gissler M, Isojärvi J, Auvinen A. Congenital structural anomalies in offspring of women with epilepsy-a populationbased cohort study in Finland. Int J Epidemiol 2006;35:280-287.

  16. Mutchinick O, Lisker R, Babinski V. The Mexican program of Registration and Epidemiologic Surveillance of External Congenital Malformations. Salud Publica Mex 1988;30:88-100.

  17. Fried S, Kozer E, Nulman I, Einarson TR, Koren G. Malformation rates in children of women with untreated epilepsy: a meta-analysis. Drug Saf 2004;27:197-202.

  18. Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 2008;81:1-13.

  19. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001;153:961-968.

  20. Van Gelder MM, Van Rooij IA, Miller RK, Zielhuis GA, de Jong-van den Berg LT, Roeleveld N. Teratogenic mechanisms of medical drugs. Hum Reprod Update 2010;16:378-394.

  21. Yerby M, Koepsell T, Daling J. Pregnancy complications and outcomes in a cohort of women with epilepsy. Epilepsia 1985;26:631-635.

  22. Borthen I, Eide MG, Veiby G, Daltveit AK, Gilhus NE. Complications during pregnancy in women with epilepsy: population-based cohort study. BJOG 2009;116:1736-1742.

  23. Mawer G, Briggs M, Baker GA, Bromley R, Coyle H, Eatock J, et al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure 2010;19:112-119.

  24. Moore SJ, Turnpenny P, Quinn A, Glover S, Lloyd DJ, Montgomery T, et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 2000;37:489-497.

  25. Juárez-Olguín H, Belmont-Gómez A, Flores-Pérez J, Barranco- Garduño LM, Flores-Pérez C. Malformations in newborns associated to anticonvulsant consumption during pregnancy, experience in third level hospital of Mexico. Rev Invest Clin 2008;60:15-20.

  26. NORMA Oficial Mexicana NOM-034-SSA2-2002 Para la prevención y control de los defectos al nacimiento [Monografía en internet]. Estados Unidos Mexicanos: Secretaría de Salud, publicada el 27 de octubre de 2003 [Consultado 2012 enero 17]. Disponible en: http://www.salud.gob. mx/unidades/cdi/nom/034ssa202.html

  27. Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, et al. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009;50:1237-1246.

  28. Bertollini R, Mastroiacovo P, Segni G. Maternal epilepsy and birth defects: a case-control study in the Italian Multicentric Registry of Birth Defects (IPIMC). Eur J Epidemiol;1:67-72.

  29. Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001;344:1132-1138.

  30. Obican S, Scialli AR. Teratogenic exposures. Am J Med Genet C Semin Med Genet 2011;157:150-169.




2020     |     www.medigraphic.com